参考文献/References:
[1] Gossage AM,Braxton Hicks JA.On auricular fibrillation[J].QJM,1913,6 (4):435-440.
[2] 郭继鸿.心房颤动性心肌病[J].临床心血管病杂志,2016,32(4):319-324.
[3] Hao G,Wang X,Chen Z,et al.Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey,2012-2015[J].Eur J Heart Fail,2019,21(11):1329-1337.
[4] Wang Z,Chen Z,Wang X,et al.The disease burden of atrial fibrillation in China from a national cross-sectional survey[J].Am J Cardiol,2018,122(5):793-798.
[5] Wang TJ,Larson MG,Levy D,et al.Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study[J].Circulation,2003,107(23):2920-2925.
[6] Gopinathannair R,Etheridge SP,Marchlinski FE,et al.Arrhythmia-induced cardiomyopathies:mechanisms,recognition,and management[J].J Am Coll Cardiol,2015,66(15):1714-1728.
[7] Qin D,Mansour MC,Ruskin JN,et al.Atrial fibrillation-mediated cardiomyopathy[J].Circ Arrhythm Electrophysiol,2019,12(12):e007809.
[8] Khan MN,Ja?s P,Cummings J,et al.Pulmonary-vein isolation for atrial fibrillation in patients with heart failure[J].N Engl J Med,2008,359(17):1778-1785.
[9] Prabhu S,Taylor AJ,Costello BT,et al.Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study[J].J Am Coll Cardiol,2017,70(16):1949-1961.
[10] Hunter RJ,Berriman TJ,Diab I,et al.A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial)[J].Circ Arrhythm Electrophysiol,2014,7(1):31-38.
[11] di Biase L,Mohanty P,Mohanty S,et al.Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial[J].Circulation,2016,133(17):1637-1644.
[12] Heist EK,Ruskin JN.Atrial fibrillation and congestive heart failure:risk factors,mechanisms,and treatment[J].Prog Cardiovasc Dis,2006,48(4):256-269.
[13] Olson TM,Michels VV,Ballew JD,et al.Sodium channel mutations and susceptibility to heart failure and atrial fibrillation[J].JAMA,2005,293(4):447-454.
[14] Orlando JR,van Herick R,Aronow WS,et al.Hemodynamics and echocardiograms before and after cardioversion of atrial fibrillation to normal sinus rhythm[J].Chest,1979,76(5):521-526.
[15] Shapiro W,Klein G.Alterations in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm[J].Circulation,1968,38(6):1074-1084.
[16] D’Amario D,Migliaro S,Borovac JA,et al.Microvascular dysfunction in heart failure with preserved ejection fraction[J].Front Physiol,2019,10:1347.
[17] Ling LH,Khammy O,Byrne M,et al.Irregular rhythm adversely influences calcium handling in ventricular myocardium: implications for the interaction between heart failure and atrial fibrillation[J].Circ Heart Fail,2012,5(6):786-793.
[18] Pandey A,Kim S,Moore C,et al.Predictors and prognostic implications of?incident heart failure in patients with?prevalent atrial fibrillation[J].JACC Heart Fail,2017,5(1):44-52.
[19] Prabhu S,Taylor AJ,Costello BT,et al.Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study[J].J Am Coll Cardiol,2017,70(16):1949-1961.
[20] Liu T,Korantzopoulos P,Shao Q,et al.Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis[J].Europace,2016,18(5):672-678.
[21] 中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.
[22] Uskach TM,Safiullina AA,Makeev MI,et al.The effect of angiotensin receptors and neprilysin inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation[J].Kardiologiia,2019,59(10S):64-72.
[23] 潘东,罗勇.沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,41(2):114-117.
[24] McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[25] Solomon SD,McMurray JJV,Anand IS,et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J].N Engl J Med,2019,381(17):1609-1620.
[26] Elayi CS,Shohoudi A,Moodie E,et al.Digoxin,mortality,and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis[J].Int J Cardiol,2020,313:48-54.
[27] Suzuki S,Motoki H,Kanzaki Y,et al.Prognostic significance of resting heart rate in atrial fibrillation patients with heart failure with reduced ejection fraction[J].Heart Vessels,2020,35(8):1109-1115.
[28] Li SJ,Sartipy U,Lund LH,et al.Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the swedish heart failure registry[J].Circ Heart Fail,2015,8(5):871-879.
[29] Chatterjee NA,Upadhyay GA,Ellenbogen KA,et al.Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review[J].Circ Arrhythm Electrophysiol,2012,5(1):68-76.
[30] Wang S,Wu S,Xu L,et al.Feasibility and efficacy of his bundle pacing or left bundle pacing combined with atrioventricular node ablation in patients with persistent atrial fibrillation and implantable cardioverter-defibrillator therapy[J].J Am Heart Assoc,2019,8(24):e014253.
[31] Calkins H,Hindricks G,Cappato R,et al.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary[J].J Arrhythm,2017,33(5):369-409.
[32] Wilton SB,Fundytus A,Ghali WA,et al.Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction[J].Am J Cardiol,2010,106(9):1284-1291.
[33] Marrouche NF,Brachmann J,Andresen D,et al.Catheter ablation for atrial fibrillation with heart failure[J].N Engl J Med,2018,378(5):417-427.
[34] Jones DG,Haldar SK,Hussain W,et al.A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure[J].J Am Coll Cardiol,2013,61(18):1894-1903.
[35] Noseworthy PA,Van Houten HK,Gersh BJ,et al.Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice[J].Heart Rhythm,2020,17(7):1057-1065.
[36] Samuel M,Abrahamowicz M,Joza J,et al.Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure[J].Europace,2020,22(5):739-747.
[37] MacDonald MR,Connelly DT,Hawkins NM,et al.Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction:a randomised controlled trial[J].Heart,2011,97(9):740-747.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(12):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(12):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(12):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(12):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(12):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(12):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]徐尧 蔡衡 李洪仕.心房颤动合并心力衰竭的导管消融治疗[J].心血管病学进展,2021,(4):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]
XU Yao,CAI Heng,LI Hongshi.Role of Radiofrequency Ablation in Patients with Atrial Fibrillation and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(12):322.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.009]